Evaluation of a Vaccine-Communication Tool for Physicians - 19/08/20
Abstract |
Objectives |
To evaluate a Kaiser Permanente Northern California physician training tool entitled “Effective Communication without Confrontation” aimed at improving communication with vaccine-hesitant parents, building trust, and alleviating physician stress surrounding vaccination visits.
Study design |
Trainings were held May to July 2015. Pre- and post-training surveys assessed physician comfort and perceived effectiveness in communicating with vaccine-hesitant parents. We measured vaccination coverage at the 2-, 4-, and 6-month well-child visits, and days undervaccinated at 9 months of age. We compared vaccination rates before and after the training.
Results |
Of 415 physicians who received training, 249 completed post-training surveys. Physicians reported that the training helped them feel “much more or more” comfortable talking with parents who are unsure (72.3%), want to delay (73.9%), or refuse (63.5%) vaccinations and “much more or more” effective at persuading parents who are unsure (67.5%) or want to delay vaccinations (61.4%). They reported feeling “the same or less” effective persuading parents who refuse vaccinations (66.3%). Vaccine coverage remained unchanged and high from before to after the training (95%-96%), as did parent satisfaction with his or her child's provider (4.73/5.00).
Conclusions |
The Effective Communication without Confrontation training did not increase vaccine coverage, but did improve physicians' comfort and perceived effectiveness communicating with most vaccine-hesitant parents and may help to ease potentially stressful vaccination visits.
Le texte complet de cet article est disponible en PDF.Keywords : immunization, vaccine hesitancy, vaccination
Abbreviations : ECC, KPNC
Plan
Funded by the Kaiser Foundation Research Institute Community Benefit. N.K. has received research grant support from Sanofi Pasteur, Novartis, GlaxoSmithKline, Merck, MedImmune, Pfizer, Protein Sciences (now Sanofi Pasteur), and Dynavax for unrelated studies. N.P. also reports potential conflicts of interest relevant to this article: the vaccines purchased by Kaiser Permanente Northern California, which are mentioned in this study, were manufactured by GlaxoSmithKline, Sanofi Pasteur, and Pfizer. The other authors declare no conflicts of interest. |
Vol 224
P. 72 - septembre 2020 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?